Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data at ASCO 2026 Meeting

**FOR IMMEDIATE RELEASE**

**Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data at ASCO Meeting 2026**

Greenwich LifeSciences presented open-label data from its FLAMINGO-01 Phase III trial at the American Society of Clinical Oncology (ASCO) meeting in 2026. The presentation detailed findings related to the company’s breast cancer therapy.

The FLAMINGO-01 trial is a Phase III study, and further details about the presented data are available in the Greenwich LifeSciences presentation materials from the ASCO meeting.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 1, 2026

Author

GOAI